Ruoyu Zhang1, Thomas Kyriss1, Jürgen Dippon2, Sebastian Ciupa3, Enole Boedeker1, Godehard Friedel1. 1. Department of Thoracic Surgery, Center for Pneumology and Thoracic Surgery, Chest Hospital Schillerhoehe, Robert-Bosch-Krankenhaus, Teaching Hospital of the University of Tuebingen, Stuttgart, Germany. 2. Institute of Stochastics and Applications, University Stuttgart, Stuttgart, Germany. 3. Department of Anaesthesia, Chest Hospital Schillerhoehe, Robert-Bosch-Krankenhaus, Teaching hospital of the University of Tuebingen, Stuttgart, Germany.
Abstract
BACKGROUND: Given the positive effect of a thoracoscopic approach on improving postoperative outcomes, it is reasonable to speculate whether an increased comorbidity burden is related to higher morbidity following thoracoscopic lobectomy. We sought to evaluate the impact of comorbidity burden on adverse postoperative outcomes in this patient population. METHODS: A retrospective review of our institutional database included 512 patients undergoing thoracoscopic lobectomy for early-stage non-small cell lung cancer (NSCLC) from 2009 through 2016. Comorbidity burden was assessed by the Charlson comorbidity index (CCI) and classified as high (CCI ≥3) or low (CCI <3) grade. Propensity score matching and random effects model were performed. RESULTS: Patients included 228 women and 284 men with a median age of 67 years. High and low comorbidity burdens were found in 193 and 319 patients, respectively. The postoperative mortality, pulmonary and cardiovascular complication rates and overall morbidity in patients with high comorbidity burden were comparable to those with low comorbidity burden (1.6% vs. 0.6%, 9.3% vs. 8.5%, 6.2% vs. 6.0%, 24.4% vs. 22.9%, respectively). Similar results were seen after propensity score matching, which balanced differences in demographics and preoperative characteristics between the comorbidity groups. On the analyses of propensity-matched data using generalized linear mixed model, a high comorbidity burden was not related to greater postoperative complication rates. CONCLUSIONS: Our results suggest that thoracoscopic lobectomy can be performed with low mortality and reasonable morbidity in lung cancer patients presenting with multiple comorbid diseases. The presence of a high comorbidity burden measured by CCI does not have a perceptible impact on adverse postoperative outcomes following thoracoscopic lobectomy.
BACKGROUND: Given the positive effect of a thoracoscopic approach on improving postoperative outcomes, it is reasonable to speculate whether an increased comorbidity burden is related to higher morbidity following thoracoscopic lobectomy. We sought to evaluate the impact of comorbidity burden on adverse postoperative outcomes in this patient population. METHODS: A retrospective review of our institutional database included 512 patients undergoing thoracoscopic lobectomy for early-stage non-small cell lung cancer (NSCLC) from 2009 through 2016. Comorbidity burden was assessed by the Charlson comorbidity index (CCI) and classified as high (CCI ≥3) or low (CCI <3) grade. Propensity score matching and random effects model were performed. RESULTS: Patients included 228 women and 284 men with a median age of 67 years. High and low comorbidity burdens were found in 193 and 319 patients, respectively. The postoperative mortality, pulmonary and cardiovascular complication rates and overall morbidity in patients with high comorbidity burden were comparable to those with low comorbidity burden (1.6% vs. 0.6%, 9.3% vs. 8.5%, 6.2% vs. 6.0%, 24.4% vs. 22.9%, respectively). Similar results were seen after propensity score matching, which balanced differences in demographics and preoperative characteristics between the comorbidity groups. On the analyses of propensity-matched data using generalized linear mixed model, a high comorbidity burden was not related to greater postoperative complication rates. CONCLUSIONS: Our results suggest that thoracoscopic lobectomy can be performed with low mortality and reasonable morbidity in lung cancer patients presenting with multiple comorbid diseases. The presence of a high comorbidity burden measured by CCI does not have a perceptible impact on adverse postoperative outcomes following thoracoscopic lobectomy.
Authors: Richard J Battafarano; Jay F Piccirillo; Bryan F Meyers; Han-Shui Hsu; Tracey J Guthrie; Joel D Cooper; G Alexander Patterson Journal: J Thorac Cardiovasc Surg Date: 2002-02 Impact factor: 5.209
Authors: Bryan M Burt; Andrzej S Kosinski; Joseph B Shrager; Mark W Onaitis; Tracey Weigel Journal: J Thorac Cardiovasc Surg Date: 2014-03-13 Impact factor: 5.209
Authors: Derek Grose; David S Morrison; Graham Devereux; Richard Jones; Dave Sharma; Colin Selby; Kirsty Docherty; David McIntosh; Greig Louden; Marianne Nicolson; Donald C McMillan; Robert Milroy Journal: Postgrad Med J Date: 2014-03-27 Impact factor: 2.401
Authors: Joshua E Rosen; Jacquelyn G Hancock; Anthony W Kim; Frank C Detterbeck; Daniel J Boffa Journal: Ann Thorac Surg Date: 2014-10-18 Impact factor: 4.330
Authors: John N Melvan; Manu S Sancheti; Theresa Gillespie; Dana C Nickleach; Yuan Liu; Kristin Higgins; Suresh Ramalingam; Joseph Lipscomb; Felix G Fernandez Journal: J Am Coll Surg Date: 2015-04-16 Impact factor: 6.113
Authors: Felix G Fernandez; Andrzej S Kosinski; William Burfeind; Bernard Park; Malcolm M DeCamp; Christopher Seder; Blair Marshall; Mitchell J Magee; Cameron D Wright; Benjamin D Kozower Journal: Ann Thorac Surg Date: 2016-05-19 Impact factor: 4.330
Authors: Max Kates; Xavier Perez; Julie Gribetz; Scott J Swanson; Thomas McGinn; Juan P Wisnivesky Journal: Am J Respir Crit Care Med Date: 2008-11-21 Impact factor: 21.405